Clinical Trial

Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase II clinical trial evaluating the efficacy and safety of HRS-7249 and SHR-1918 in patients with severe hypertriglyceridemia at high risk of acute pancreatitis
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-15; most recent amendment 2026-05-24.
Status change: Not Yet Recruiting → Recruiting 2026-02-27
Trial Details
NCT Number NCT07308392
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis
Enrollment 108 participants
Start Date 2026-02-25
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-28